Rush hymenoptera venom immunotherapy is efficacious and safe

Journal of Investigational Allergology and Clinical Immunology

Volumn 16, Issue 4, 2006, Pages 232-238

  Pasaoglu, G ^a,b   Sin, B A ^a   Misirligil, Z ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Efficacy; Safety; Venom immunotherapy

Indexed keywords

BEE VENOM; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INSECT VENOM; UNCLASSIFIED DRUG; VESPULA VENOM EXTRACT; YELLOW JACKET VENOM EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC REACTION; ALLERGY; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYMENOPTERA; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION SITE REACTION; INSECT STING; MALE; PATIENT MONITORING; PRICK TEST; SKIN TEST;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANIMALS; ARTHROPOD VENOMS; BEE VENOMS; CASE-CONTROL STUDIES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYMENOPTERA; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INSECT BITES AND STINGS; MALE; MIDDLE AGED; SAFETY; SKIN TESTS; TIME FACTORS; TURKEY; WASP VENOMS;

EID: 33746896669     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ditto AM. Hymenoptera sensitivity: diagnosis and treatment. Allergy Asthma Proc. 2002;23:381-4.
2. Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027-32.
3. Bonifazi F, Jutel M, Bilo MB, Birnbaum J, Müller U. EAACI Position Paper. Prevention and treatment of hymenoptera venom allergy. Allergy. 2005; 1-25. Available from www.eaaci.net.
4. Hunt K, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978; 299:257-61.
5. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of hymenoptera venom immunotherapy. Ann Intern Med. 1980; 92: 620-4.
6. Birnbaum J, Charpin D, Vervloet D. Rapid hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy. 1993; 23: 226-30.
7. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210min): a safety study and risk factors. Clin Exp Allergy. 2003;33:58-64.
8. Golden DB, Kagey-Sobotka A, Valentine MD, Linchtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1981;67:370-4.
9. Bousquet J, Menardo JL, Velasquez G, Michel FB. Systemic reactions during maintenance immunotherapy with honeybee venom. Ann Allergy. 1988;61:63-8.
10. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992;89:529-35.
11. Müller U, Mosbech H. Position paper: immunotherapy with Hymenoptera venoms. Allergy. Suppl. 1996;48:37-46.
12. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;1:466-9.
13. Demoly P, Michel FB, Bousquet J. In vivo methods for study of allergy skin tests, and interpretation. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, eds. Allergy Principles and Practice. 5th ed. Mosby, St. Louis, 1998:430-39.
14. Scribner TA, Bernstein DI. Rapid venom immunotherapy update. Curr Opin Allergy Clin Immunol. 2003;3:295-8.
15. Berchtold E, Maibach R, Müller U. Reduction of side effects from ultrarush immunotherapy with honey bee venom by pre-treatment with terfenadine. Clin Exp Allergy. 1992;22:59-65.
16. Laurent J, Smiejan JM, Bloch-Morot E, Herman D. Safety of Hymenoptera venom rush immunotherapy. Allergy. 1997;52:94-6.
17. Mosbech H, Müller U. Side-effect of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55:1005-10.
18. Brehler R, Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol. 2000;105:1231-5.
19. Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T, Gerdsen R. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy. 2003;58:1176-9.
20. Diez Gomez ML, Quirce Gancedo S, Juia de Paramo B. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. Allergol Immunopathol. 1995;23:277-84.
21. Lockey R, Turkeltaub P, Olive E, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study III. Safety of venom immunotherapy. J Allergy Clin Immunol. 1990;86:775-80.
22. Youlten L, Atkinson B, Lee T. The incidence and nature of adverse reaction to injection immunotherapy in bee and wasp venom allergy. Clin Exp Allergy. 1995;25:159-65.
23. Sturm G, Kranke B, Rudolph C, Aberer W. Rush hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol. 2002; 110:928-33.
24. Sanchez F, Blanca M, Miranda A, Garcia J, Fernandez J, Torres MJ, Rondon MC, Juarez C. Comparison of Vespula germanica venoms obtained from different sources. Int Arch Allergy Immunol. 1994; 104:385-9.
25. Wood CL, Timmons BE 4th, Hoffman DR. Allergens in Hymenoptera venoms. X. Vespid venoms versus venom sac extracts: comparison by two-dimensional polyacrylamide gel electrophoresis. Ann Allergy. 1983;51:441-5.
26. Cadario G, Marengo F, Ranghino E, Rossi R, Gatti B, Cantone R, Bona F, Pellegrino R, Feyles G, Puccinelli P, Burastero SE. Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy. J Invest Allergol Clin Immunol. 2004;14:127-33.
27. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergy to bee venom. J Allergy Clin Immunol. 1998;101:747-54.
28. Rueff F, Przybilla B. Venom immunotherapy: adverse reactions and treatment failure. Curr Opin Allergy Clin Immunol. 2004;4:307-11.
29. Irsch J, König C, Tesch H, Tesch H, Krieg T, Merk H, Radbruch A, Hunzelmann N. The frequency of phospholipase A2 binding of basophilic granulocytes does not decrease during bee-venom specific immunotherapy. Allergy. 1999;45:742-7.
30. Sobotka AK, Franklin RM, Adkinson NF, Valentine M, Baer H, Lichtenstein LM. Allergy to insect stings. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol. 1976;57:29-40.
31. Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom specific IgG antibody level during immunotherapy. J Allergy Clin Immunol. 1982;69:489-93.
32. Siegmund R, Vogelsang H, Machnik A, Herrmann D. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy. J Allergy Clin Immunol 2000;106:1190-5.
33. Müller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy. 1989;44:412-18.
34. Aalberse RC, Dieges PH, Knul-Bretlova V, Vooren P, Aalbers M, van Leeuwen J. IgG4 as a blocking antibody. Clin Rev Allergy. 1983;1:289-302.
35. Randolph CC, Reisman RE. Evaluation of decline in serum venom-specific IgE as a criterion for stopping venom immunotherapy. J Allergy Clin Immunol. 1986;77:823-7.
36. Ferrante A, Mocatta F, Goh DH. Changes in IgG and IgE antibody levels to bee venom during immunotherapy. Int Arch Allergy Appl Immunol. 1986;81:284-7.
37. Golden DB. Insect sting allergy and venom immunotherapy: A model and a mystery. J Allergy Clin Immunol. 2005;115:439-47.
38. Müller U, Heibling A, Bischof M. Predictive value of venom specific IgE, IgG and IgG subclass antibodies in patients on immunothrapy with honey bee venom. Allergy. 1989;44:412-8.
39. Stämpfli MR, Rudolf M, Miescher S, Pachlopnik JM, Stadler BM. Antigen-specific inhibition of IgE binding to the high affinity receptor. J Immunol. 1995;155:2948-54.
40. Frew AJ. Immunotherapy of allergic disease. J Allergy Clin Immunol. 2003;111:S712-9
41. Jutel M, Akdis M, Blaser K, Akdis CA. Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol. 2005;5:365-9.
42. McHugh SM, Deighton J, Stewart AG, Ewan P. Bee venom immunotherapy induces a shift in cytokine responses from a TH2 to a TH1 dominant pattern: a comparison of rush and conventional immunotherapy. Clin Exp Allergy. 1995;25:828-38.
43. Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, Lombardo C, Roncallo C, Patriarca G. Specific ultrarush desensitization in hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. 2004;92:409-13.